Bristol-Myers Squibb Co (NYSE:BMY) EVP Louis S. Schmukler sold 25,000 shares of the company’s stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $62.68, for a total value of $1,567,000.00. Following the transaction, the executive vice president now directly owns 26,777 shares in the company, valued at approximately $1,678,382.36. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Shares of Bristol-Myers Squibb stock opened at $60.79 on Friday. The company has a current ratio of 1.66, a quick ratio of 1.51 and a debt-to-equity ratio of 0.86. The firm has a market capitalization of $138.34 billion, a PE ratio of 75.05, a price-to-earnings-growth ratio of 1.21 and a beta of 0.74. The business’s 50-day moving average price is $60.48 and its 200-day moving average price is $60.71. Bristol-Myers Squibb Co has a 12 month low of $42.48 and a 12 month high of $68.34.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $1.72 EPS for the quarter, beating the consensus estimate of $1.49 by $0.23. The firm had revenue of $10.78 billion for the quarter, compared to analyst estimates of $10.04 billion. Bristol-Myers Squibb had a return on equity of 30.06% and a net margin of 3.08%. The company’s revenue was up 82.1% on a year-over-year basis. During the same period in the prior year, the company earned $1.10 EPS. As a group, analysts predict that Bristol-Myers Squibb Co will post 6.15 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, May 1st. Stockholders of record on Friday, April 3rd were given a dividend of $0.45 per share. The ex-dividend date was Thursday, April 2nd. This represents a $1.80 annualized dividend and a dividend yield of 2.96%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 38.38%.

Institutional investors have recently made changes to their positions in the company. Stonebridge Financial Planning Group LLC bought a new position in Bristol-Myers Squibb during the 4th quarter worth approximately $26,000. grace capital bought a new position in Bristol-Myers Squibb during the 4th quarter worth approximately $26,000. Birch Capital Management LLC bought a new position in Bristol-Myers Squibb during the 4th quarter worth approximately $28,000. JCIC Asset Management Inc. bought a new position in Bristol-Myers Squibb during the 1st quarter worth approximately $25,000. Finally, Perennial Advisors LLC bought a new position in Bristol-Myers Squibb during the 1st quarter worth approximately $27,000. Hedge funds and other institutional investors own 76.51% of the company’s stock.

A number of research analysts have recently commented on BMY shares. Societe Generale cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $50.00 price target on the stock. in a research report on Monday, March 23rd. TheStreet cut Bristol-Myers Squibb from a “b-” rating to a “c+” rating in a research report on Monday, April 13th. ValuEngine cut Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Wednesday, April 29th. Cfra increased their price objective on Bristol-Myers Squibb from $69.00 to $70.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Finally, Bank of America reissued a “buy” rating and set a $80.00 price objective on shares of Bristol-Myers Squibb in a report on Friday, May 15th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and twelve have issued a buy rating to the company. Bristol-Myers Squibb has a consensus rating of “Buy” and a consensus target price of $65.38.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Read More: Stock Split

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.